Cristalia Produtos Quimicos Farmaceuticos Ltda.

Fundacao Butantan

Genpharma Consultoria Farmaceutica E Genetica Ltda.

Ogari De Castro Pacheco

Roberto Carlos Debom Moreira

Marcos Castanheira Alegria

Josef Ernst Thiemann

Spartaco Astolfi Filho

Lucidio Cristovao Fardelone

Marina Baiochi Riboldi Delalana

Elisa Mannochio De Souza Russo

Denise Vilarinho Tambourgi

Osvaldo Augusto Brazil Esteves Sant'Anna

Fábio Carlos Magnoli

Krishnamurti De Morais Carvalho

Dòris Maria Fernandes Carvalho

Maria Denise Fernandes Carvalho

Giselle Pidde Queiroz

Valter Freiro Torres Russo

Denise V Tambourgi

Lucidio Cristóvão Fardelone

Dóris Maria Fernandes Carvalho

The present invention refers to a culture medium and a process for producing proteases with collagenolytic and gelatinolytic activity by bacteria of the genus. Particularly, the present invention refers to an animal product-free culture medium for, characterized by comprising non-animal origin peptones, preferably vegetable peptones, yeast extract and the amino acids cysteine and arginine. The present invention also refers to a process for producingliquid culture supernatant comprising one or more proteases with collagenolytic and gelatinolytic activity, and pharmaceutical composition comprising as active ingredient the supernatant or the supernatant optionality purified.

Animal product-free culture medium for bacteria of the genusand a process for producing supernatant comprising one or more collagenolytic and gelatinolytic proteases

This invention refers to polynucleotides and non-hemorrhagic and non-immunogenic polypeptides of selective immunosuppressive activity on production of antibodies to antigens of different natures. The polypeptides described herein are useful for preparing pharmaceutical compositions for prevention or treatment of conditions that require immunosuppression, preferably, inflammatory, autoimmune, allergic and infectious diseases and rejection to transplanted organs.

Polynucleotide, polypeptide with immunosuppressive activity, expression cassette, expression vector, host cell, pharmaceutical composition, methods for producing a polypeptide with immunosuppressive activity and for preventing or treating conditions that require immunosuppression, and use of a polypeptide

The present invention refers to a culture medium and a process for producingcollagenolytic and gelatinolytic proteases. The present invention includes an animal product-free culture medium forcomprising non-animal derived peptones, preferably vegetable derived peptones, yeast extract and the amino acids cysteine and arginine. The present invention also includes a process for producing a supernatant ofliquid culture comprising one or more collagenolytic and gelatinolytic proteases, and pharmaceutical composition comprising as active ingredient a supernatant of thecultures described herein.

Animal product-free culture medium and a process for producing a supernatant of clostridium comprising one or more collagenolytic and gelatinolytic proteases

The present invention is directed to the use of telocinobufagin, or its pharmaceutically acceptable derivatives, in the manufacture of a medicament for the treatment or prevention of acute and chronic pains. The present invention also refers to a pharmaceutical composition comprising an effective amount of telocinobufagin; also provides a method to induce analgesia in response to acute and chronic pains that comprehends administering an effective amount of telocinobufagin to human beings or animals. According to the outcomes of in vivo assays, telocinobufagin is more potent than morphine, though without presenting the known side effects of opioids. In addition, in vivo and in vitro essays showed that TBC does not present cardiotoxicity.

Use of telocinobufagin as an analgesic in the treatment of acute and chronic pains

The present invention describes a method of separation of the enantiomers of N-(2,6-dimethylphenyl)-1-propyl-2-piperidinocarboxamide. Another object of the present invention refers to the enantiomeric manipulation of the enantiomers of N-(2,6-dimethylphenyl)-1-propyl-2-piperidinocarboxamide, in order to achiever compounds and pharmaceutical compositions presenting diverse enantiomeric excesses of (S)-N-(2,6-dimethylphenyl)-1-propyl-2-piperidinocarboxamide, in order to quantify and determine the participation of (R)-N-(2,6-dimethylphenyl)-1-propyl-2-piperidinocarboxamide in the anesthetic and cardiotoxic effects. These compounds and compositions enantiomerically manipulated demonstrate to present a significant improvement in itsanesthetic properties, presenting a cardiotoxic profile equivalent to pure enantiomer, a (S)-N-(2,6-dimethylphenyl)-1-propyl-2-piperidinocarboxamide. 

Non-racemic mixtures of (S) and (R) enantiomers of N-(2,6-dimethylphenyl)-1-propyl-2-piperidinocarboxamide; related processes and pharmaceutical compositions

Growing community of inventors

Itapira, Brazil

Ogari De Castro Pacheco